Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12288906 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2HRH3RAB9ANPC1KDM4E | |
| SCHEMBL2554131 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2556060 | 0.81 | HRH3 (0.56) | SMN1; SMN2HRH3RAB9ANPC1KDM4E | |
| SCHEMBL2559606 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2557752 | 0.78 | RAB9A (0.62) | SMN1; SMN2HRH3RAB9ANPC1 | |
| SCHEMBL2554399 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2 | |
| SCHEMBL2571315 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2HRH3RAB9ANPC1MAPT | |
| SCHEMBL2557161 | 0.74 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL2560486 | 0.74 | SMN1; SMN2 (0.66) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL2574756 | 0.74 | RAB9A (0.61) | SMN1; SMN2HRH3RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | claimed |
| WO-2011130515-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-20 | — | — | WO | claimed |
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SMN1; SMN2, MTPN, MORF4L1 | SMN1; SMN2 1/4885HRH3 4201/4885RAB9A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.